A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma

Trial Profile

A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Buparlisib; Capmatinib; Infigratinib; Ribociclib
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms LOGIC-2
  • Sponsors Array BioPharma; Novartis
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 29 Mar 2017 Planned End Date changed from 1 Jul 2017 to 1 Mar 2018.
    • 29 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top